Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) is a clinical-stage drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic inflammatory disease and neurologic disorders. The company’s lead compound, anatabine citrate, is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics that are distinct from other anti-inflammatory drugs currently on the market. Rock Creek has also sponsored extensive pre-clinical studies resulting in peer-reviewed and published scientific journal articles. For more information, visit the company’s website at www.rockcreekpharmaceuticals.com.